PDCD1LG2 and neoplasm: PD-1 binds to programmed death protein ligand-1(PD-L1) or programmed death protein ligand-2(PD-L2), which inhibits the activation of T cells and makes T cells lose their antitumor activity, thus changing the tumor microenvironment and inhibiting immune response [18, 19].